Abdullah E. Sakin

Istanbul, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Development of a biomarker-guided chemotherapy response model using combined CEA and CA19-9 profiles in esophageal cancer: A real-world pharmacotherapeutic study.

Development of a biomarker-guided chemotherapy response model using combined CEA and CA19-9 profiles in esophageal cancer: A real-world pharmacotherapeutic study.

Journal: Pakistan journal of pharmaceutical sciences

Published: September 08, 2026

Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.

Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.

Journal: Immunotherapy

Published: September 02, 2026

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Journal: Cancers

Published: May 12, 2026

First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

Journal: Medicina (Kaunas, Lithuania)

Published: April 15, 2026

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 06, 2026

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 06, 2026

The role of serum adipokines in predicting response to neoadjuvant therapy in patients with locally advanced rectal cancer.

The role of serum adipokines in predicting response to neoadjuvant therapy in patients with locally advanced rectal cancer.

Journal: Revista da Associacao Medica Brasileira (1992)

Published: December 14, 2025

Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study.

Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study.

Journal: Cancer investigation

Published: December 05, 2025

Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study.

Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study.

Journal: BMC cancer

Published: November 30, 2025

The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.

The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.

Journal: Medicina (Kaunas, Lithuania)

Published: November 24, 2025

Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study.

Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study.

Journal: Cancer management and research

Published: November 21, 2025

Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program.

Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program.

Journal: Future oncology (London, England)

Published: October 17, 2025

Showing 1-12 of 111

Last Updated: 09/26/2026